ARCHIVES

Letters to the Editor: Burzynski: Reviewers Sought To Discredit Antineoplaston Therapy

This article is from The Cancer Letter archive.

Vol. 24 No. 41 | October 30, 1998

Download PDF Visit The Full Archive

Related Articles

UCLA Comp Center status Near, But There Are Problems

October 22, 1976

More Cost-Effective To Use Cetuximab In Patients With Wild-Type KRAS Gene

August 28, 2009

FDA Proposes To Require Electronic Submission

May 3, 2002

Cancer Groups Support Senate FDA Bill; Reform Measure Face Uncertain future

March 1, 1996

Edelson to Direct Yale Cancer Center (12-page issue).

May 30, 2003

FDA Approves Tamoxifen For DCIS Folowing Breast Surgery And Radiation.

July 28, 2000